Titan Spine announced that it has entered into a distribution agreement with MBA as a strategic partner to provide Titan’s line of Endoskeleton titanium implants to practicing spine surgeons in six countries across Europe.

Under the agreement, Titan Spine will provide its spinal interbody fusion devices featuring its proprietary surface technology to MBA for distribution in Spain, Portugal, Andorra, Luxembourg, Belgium and the United Kingdom (UK).

MBA is a prominent international medical device marketing-and-distribution organization that specializes in the sale of products used for orthopedic and neurosurgery treatments.

In addition, Titan Spine recently opened an office in Valencia, Spain to support the growing European adoption of its Endoskeleton devices. The Spain office supports sales, training and marketing initiatives across Europe in conjunction with Titan’s European headquarters located in Laichingen, Germany.

In addition, the Spain office operates in a strategic capacity to facilitate distribution efforts and relations within the Spanish and Portuguese markets, which are quickly adopting the Company’s titanium devices featuring its proprietary surface technology.

Marcus Klarl, Vice President of Sales, Europe for Titan Spine, commented, "MBA is one of the leaders in distribution of orthopedic and neurosurgical products throughout Europe and offers us a strategic alliance to penetrate the major markets of Spain, Portugal, Belgium and the UK, which was a critical objective we hoped to achieve this year.

Kevin Gemas, President of Titan Spine, added, "Titan Spine has experienced significant sales growth over the last few years, with particular uptick over the first half of 2015."

The full line of Endoskeleton devices features Titan Spine’s proprietary implant surface technology, consisting of a unique combination of roughened topographies at the macro, micro, and cellular levels created by a subtractive process.

This unique combination of surface topographies is designed to create an optimal host-bone response and actively participate in the fusion process by promoting the upregulation of osteogenic and angiogenic factors necessary for bone growth, encouraging natural production of bone morphogenetic proteins (BMPs), and creating the potential for a faster and more robust fusion.